Walmart agreed to pay a $3.1 billion settlement over lawsuits linking it to the opioid epidemic. Walmart follows both CVS and Walgreens in striking deals over their role in the crisis. (The New York Times)

The Food and Drug Administration has granted ImmunoGen’s ovarian cancer drug accelerated approval, with a confirmatory trial set to provide results by next year. The drug, mirvetuximab soravtansine, will be branded as Elahere. (Endpoints News)

Amazon is launching Amazon Clinic, a virtual care platform that will connect patients with providers for treatment of 20 different health conditions, including allergies and migraines. The news comes a few months after the company said it would no longer offer Amazon Care primary health care services. (GeekWire)

The demand for obesity drugs like Novo Nordisk’s Wegovy is so great that the company isn’t too worried about the entrance of rival drugs, Novo Nordisk CEO Lars Jorgensen said on Tuesday. Wegovy was approved for weight loss therapy in 2021. (Reuters)

The Food and Drug Administration announced that opioid overdose reversal agent naloxone could potentially be safe and effective as an over-the-counter product. The agency will explore the possibility of approving non-prescription naloxone products. (FDA)